Trial Profile
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of a Haploidentical Hematopoietic Stem Cell Transplant
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2018
Price :
$35
*
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 19 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to PI withdrawl
- 02 Jul 2018 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.
- 02 Jul 2018 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.